Oncology clinical pathways and clinical decision support (CDS) tools have been part of the oncology landscape in one form or another for many years. Pathways are increasingly common and can assist providers in navigating the increasingly complex set of treatment selections.
Our recent column highlights HMP Market Access Insights’ (MAI) research on oncologists’ awarenesses of pathways and the factors driving adoption. Our 2023 Oncology Clinical Pathways study focused on quantifying the influence and impact pathways have on oncologists’ treatment decisions by conducting a unique two-arm study with 132 oncologists using advanced conjoint analysis. Key findings include:
The ATOPP Summit covered a range of cutting-edge topics, including the shift toward administering cellular therapies to patients in community oncology settings.
Emma Bijesse, Daniel BuchenbergerWelcome to the June 2024 edition of our Monthly Insight Series! This month we’re discussing oncology clinic concerns with existing manufacturer engagement approaches, using data drawn from our 2024 Community Oncology report, coming later in June.
Ashutosh ShethWhile provider-initiated oncology clinical pathways are regaining momentum, payer pathways struggle to find a foothold in this space. Still, they can exert impact under certain conditions.
Cindy Chen